CPC A61K 31/713 (2013.01) [A61K 47/61 (2017.08); A61K 47/645 (2017.08); A61P 21/06 (2018.01)] | 16 Claims |
1. A method for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms, the method comprising:
determining that the subject is a target subject who exhibits onset of ME/CFS symptoms between 2 to 8 years prior to treatment; and
administering to the target subject a pharmaceutical composition comprising as an active ingredient an effective amount of a therapeutic dsRNA (tdsRNA);
wherein the tdsRNA is rIn·r(C12U)n and
wherein n is an integer from 40 to 50,000.
|